OncoMatch/Clinical Trials/NCT06682130
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Is NCT06682130 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Group A：Patients with PR or ctDNA positivity after salvage treatment and Group C: Patients with SD/PD after posterior treatment for diffuse large b-cell lymphoma(dlbcl).
Treatment: Group A：Patients with PR or ctDNA positivity after salvage treatment · Group C: Patients with SD/PD after posterior treatment — The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplantation
Lab requirements
Blood counts
Hemoglobin ≥ 9g/dL, Platelet count ≥ 70 × 10^9/L, The absolute value of neutrophils is ≥ 1.0 × 10^9/L, If accompanied by bone marrow invasion, platelet count ≥ 50 × 10^9/L, absolute neutrophil count ≥ 0.75 × 10^9/L, The number of CD34+cells is ≥ 2.0 × 10^9/kg
Kidney function
serum creatinine clearance rate ≥ 80 mL/min, creatinine <160 umol/l
Liver function
alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal, total bilirubin <2 times the upper limit of normal
Cardiac function
ejection fraction ≥ 50%, asymptomatic arrhythmia
Cardiac function: ejection fraction ≥ 50%, asymptomatic arrhythmia; Liver function: alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal, total bilirubin <2 times the upper limit of normal; Renal function: serum creatinine clearance rate ≥ 80 mL/min, creatinine <160 umol/l; Pulmonary function: Without oxygen inhalation, SPO2 >90%, FEV1, FVC, and DLCO ≥ 50% predicted values; Adequate bone marrow reserve is defined as: Hemoglobin ≥ 9g/dL, Platelet count ≥ 70 × 10^9/L, The absolute value of neutrophils is ≥ 1.0 × 10^9/L, If accompanied by bone marrow invasion, platelet count ≥ 50 × 10^9/L, absolute neutrophil count ≥ 0.75 × 10^9/L, The number of CD34+cells is ≥ 2.0 × 10^9/kg.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify